NO911174L - Kermesbaer antiviralt protein (pap)-monoklonalt antistoffkonjugat. - Google Patents

Kermesbaer antiviralt protein (pap)-monoklonalt antistoffkonjugat.

Info

Publication number
NO911174L
NO911174L NO91911174A NO911174A NO911174L NO 911174 L NO911174 L NO 911174L NO 91911174 A NO91911174 A NO 91911174A NO 911174 A NO911174 A NO 911174A NO 911174 L NO911174 L NO 911174L
Authority
NO
Norway
Prior art keywords
pap
monoclonal antibody
kermesbaer
antiviral protein
antibody conjugate
Prior art date
Application number
NO91911174A
Other languages
English (en)
Norwegian (no)
Other versions
NO911174D0 (no
Inventor
Fatih M Uckun
Joyce M Zarling
Original Assignee
Univ Minnesota
Oncogen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Minnesota, Oncogen filed Critical Univ Minnesota
Publication of NO911174D0 publication Critical patent/NO911174D0/no
Publication of NO911174L publication Critical patent/NO911174L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817Toxins
    • A61K47/6819Plant toxins
    • A61K47/6825Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • AIDS & HIV (AREA)
  • Cell Biology (AREA)
  • Botany (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO91911174A 1989-07-25 1991-03-22 Kermesbaer antiviralt protein (pap)-monoklonalt antistoffkonjugat. NO911174L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38531489A 1989-07-25 1989-07-25
US50352290A 1990-03-30 1990-03-30
PCT/US1990/003921 WO1991001145A1 (en) 1989-07-25 1990-07-12 Pokeweed antiviral protein - monoclonal antibody conjugates

Publications (2)

Publication Number Publication Date
NO911174D0 NO911174D0 (no) 1991-03-22
NO911174L true NO911174L (no) 1991-05-24

Family

ID=27010961

Family Applications (1)

Application Number Title Priority Date Filing Date
NO91911174A NO911174L (no) 1989-07-25 1991-03-22 Kermesbaer antiviralt protein (pap)-monoklonalt antistoffkonjugat.

Country Status (17)

Country Link
EP (1) EP0441917B1 (fi)
JP (1) JP3109678B2 (fi)
KR (1) KR920700698A (fi)
AT (1) ATE137410T1 (fi)
AU (1) AU631674B2 (fi)
CA (1) CA2037900C (fi)
DE (1) DE69026812T2 (fi)
DK (1) DK0441917T3 (fi)
ES (1) ES2087158T3 (fi)
FI (1) FI911447A0 (fi)
GR (1) GR1002180B (fi)
IE (1) IE74143B1 (fi)
IL (1) IL95134A (fi)
NO (1) NO911174L (fi)
NZ (1) NZ234607A (fi)
PT (1) PT94789B (fi)
WO (1) WO1991001145A1 (fi)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0425604U (fi) * 1990-06-27 1992-02-28
GB9217124D0 (en) * 1992-08-13 1992-09-23 Antisoma Ltd Medical treatment
US6576236B1 (en) * 1994-07-01 2003-06-10 Dana Farber Cancer Institute Methods for stimulating T cell responses by manipulating a common cytokine receptor γ chain
US5919457A (en) * 1996-01-11 1999-07-06 Regents Of The University Of Minnesota TXU-5/B53-PAP antiviral biotherapeutic agent for the treatment of AIDS
PT2696687T (pt) 2011-04-12 2017-02-02 Novo Nordisk As Derivados de glp-1 duplamente acilados

Also Published As

Publication number Publication date
GR1002180B (en) 1996-03-11
DK0441917T3 (da) 1996-09-16
ATE137410T1 (de) 1996-05-15
JPH04502625A (ja) 1992-05-14
WO1991001145A1 (en) 1991-02-07
IE74143B1 (en) 1997-07-02
JP3109678B2 (ja) 2000-11-20
NZ234607A (en) 1992-10-28
NO911174D0 (no) 1991-03-22
FI911447A0 (fi) 1991-03-25
IE902593A1 (en) 1991-02-27
PT94789B (pt) 1997-04-30
CA2037900A1 (en) 1991-01-26
EP0441917A1 (en) 1991-08-21
KR920700698A (ko) 1992-08-10
AU631674B2 (en) 1992-12-03
DE69026812T2 (de) 1996-11-28
CA2037900C (en) 1999-11-16
IL95134A (en) 1996-01-31
DE69026812D1 (de) 1996-06-05
AU6140590A (en) 1991-02-22
IL95134A0 (en) 1991-06-10
GR900100550A (el) 1991-12-10
EP0441917B1 (en) 1996-05-01
ES2087158T3 (es) 1996-07-16
PT94789A (pt) 1991-03-20

Similar Documents

Publication Publication Date Title
ES2174837T3 (es) Conjugados de saponina-antigeno y su utilizacion.
FI932561A0 (fi) Proteiner med foeraendrade epitoper och foerfaranden foer deras framstaellning
DE3585087D1 (de) Retrovirale polypeptide in zusammenhang mit menschlicher transformation.
DE69014474D1 (de) Antikörper gegen TNF-Bindungsprotein I und deren F(ab)-Fragmente.
NO881077D0 (no) Kjemo-radio-immuno-konjugater.
DK160842C (da) Vandoploeselige konjugater af superoxiddismutase, samt farmaceutisk praeparat indeholdende konjugatet
NO911174D0 (no) Kermesbaer antiviralt protein (pap)-monoklonalt antistoffkonjugat.
ES2080047T3 (es) Peptidos hiv y metodos para la deteccion de hiv.
FR2637897B1 (fr) Dosages immunologiques de l'azt, derives et conjugues et anticorps
DE69231495D1 (de) Neue cocain-derivate und protein- und polypeptid-cocain-derivate, konjugate und markierte verbindungen
ES2043900T3 (es) Conjugados de haptenos y proteinas y su utilizacion.
DK314886D0 (da) Histamin-derivat og -immunogen-konjugat, cellelinie og antistof produceret deraf samt immunbestemmelse af histamin ved hjaelp af antistoffet
DE69034209D1 (de) 2'-deoxy-4'-thioribonucleoside als antivirale und antikrebsmittel
DE3670307D1 (de) Spezifische mycoplasma-membran-antigene und -antikoerper sowie deren klinische verwendungen.
KR900011795A (ko) 고무변성스티렌계 공중합체
NO870779L (no) Opploeseliggjoering av proteiner for farmasoeytiske preparater ved bruk av polymerkonjugasjon.
DK74590D0 (da) In vitro-syntese af et infektioest rna
SE9002479D0 (sv) Antibody conjugates
SE8902432D0 (sv) Antibody conjugates
IT1229534B (it) Dispositivo da tavolo per l'estrazione singola di fogli per annotazioni e simili
ES1015772Y (es) Perfeccionamientos en piezas para union de colgantes.
KR900016456U (ko) 남자용 팬티